<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03013894</url>
  </required_header>
  <id_info>
    <org_study_id>2015_300</org_study_id>
    <nct_id>NCT03013894</nct_id>
  </id_info>
  <brief_title>Confocal Laser Endomicroscopy in the Lower Urinary Tract</brief_title>
  <official_title>Feasibility of Confocal Laser Endomicroscopy in Bladder Cancer Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Cystoscopy and cytology, the current 'gold standard' for detection and follow-up&#xD;
      of primary and recurrent bladder cancer have some limitations. CLE, a high resolution imaging&#xD;
      technique, that can be used combined with endo-urological procedures, seems promising to&#xD;
      improve diagnosis of bladder cancer. The diagnostic accuracy of cystoscopic applied confocal&#xD;
      laser endomicroscopy (CLE) still has to be defined.&#xD;
&#xD;
      Objective: To directly correlate CLE images with histopathology, and identify and define CLE&#xD;
      characteristics of normal urothelium, benign bladder urothelium, and bladder tumors&#xD;
      (low-grade, high-grade and carcinoma in situ (CIS)) of the lower urinary tract.&#xD;
&#xD;
      Primary objective: to develop descriptive image interpretation criteria and a classification&#xD;
      of CLE images of bladder tissue through a review of prospectively obtained CLE videos from&#xD;
      bladder tissue correlated with histopathology.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Assessing procedure related adverse events of CLE&#xD;
&#xD;
        -  Assessing technical feasibility of CLE&#xD;
&#xD;
        -  To develop a CLE image atlas for urothelium of the lower urinary tract (normal, benign,&#xD;
           low-grade or high-grade and CIS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, observational study; the investigators will establish&#xD;
      sensitivity and specificity of CLE ex vivo and in vivo, in the diagnosis of bladder&#xD;
      carcinoma.&#xD;
&#xD;
      Eligible patients are diagnosed with a bladder tumor at the outpatient clinic and scheduled&#xD;
      for transurethral resection of bladder tumor (TURB). In total the investigators want to&#xD;
      include 60 patients. Yearly approximately 70 patients are diagnosed with primary and&#xD;
      recurrent bladder carcinoma in the Academic Medical Center (AMC) and will undergo TURB.&#xD;
&#xD;
      Their Urologist will inform patients diagnosed with a bladder tumor who will be scheduled for&#xD;
      treatment by means of TURB about the study. Information about the study will be provided both&#xD;
      orally and in written form.&#xD;
&#xD;
      CLE images are recorded using a probe-based system (Cellvizio 100 series, Mauna Kea&#xD;
      Technologies, Paris, France). The probe (Cystoflex UHD-R, Mauna Kea Technologies, Paris,&#xD;
      France) has an outer diameter of 2.8 mm, a field of view of 240 µm and has a resolution of 1&#xD;
      µm. Images are collected at a scan rate of 12 frames per second. Using the Cellvizio Viewer&#xD;
      system, the investigators can observe mucosal microarchitecture with an increased field of&#xD;
      view through mosaic post processing. This system also enables virtual staining of mucosal&#xD;
      structures to further enhance tissue contrast.&#xD;
&#xD;
      A fluorescent contrast agent is needed to obtain CLE images. Fluorescein&#xD;
      (fluoresceinedisodium, Fresenius Kabi, Zeist, Netherlands), a non-toxic and commonly used&#xD;
      fluorescent dye will be administered intravesical (300-400 mL 0.1% fluorescein diluted in&#xD;
      saline) and left indwelling for 5 minutes to stain the extracellular matrix.&#xD;
&#xD;
      The study consists of three CLE measurements, one in vivo prior to tumor resection, the&#xD;
      second ex vivo of the resected specimen, and the last measurement is ex vivo after fixating&#xD;
      the tumor on formaldehyde. In the case of multiple tumors, multiple CLE measurements will be&#xD;
      done. The measurement per-operatively will add approximately 15 minutes to operating time. In&#xD;
      the ex vivo set up, additional images will be acquired using Optical Coherence Tomography&#xD;
      (OCT). During tumor resection, a small chip of normal urothelium will be resected&#xD;
      additionally to act as control. Resected bladder tissue will be fixed and laminated by the&#xD;
      pathology department, to correlate to CLE images.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Confocal laser endomicroscopy characteristics of urothelium of the lower urinary tract</measure>
    <time_frame>1.5 years</time_frame>
    <description>Qualitatively correlating CLE images to histopathology to define CLE characteristics</description>
  </primary_outcome>
  <enrollment type="Actual">73</enrollment>
  <condition>Bladder Neoplasm</condition>
  <condition>Urothelial Carcinoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CLE images (without DNA) and histopathology (with DNA)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients &gt;18 years old with primary or recurrent bladder tumor(s), who are scheduled for&#xD;
        TURB are eligible for this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;18 years old&#xD;
&#xD;
          -  Bladder tumor(s)&#xD;
&#xD;
          -  Candidate for TURB&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt;18 years old&#xD;
&#xD;
          -  Patients with known allergy for fluorescein&#xD;
&#xD;
          -  Possible pregnancy or lactating women&#xD;
&#xD;
          -  No signed informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean J de la Rosette, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2017</study_first_posted>
  <last_update_submitted>June 5, 2018</last_update_submitted>
  <last_update_submitted_qc>June 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Prof.dr. J.J.M.C.H. de la Rosette</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>bladder neoplasm</keyword>
  <keyword>urothelium carcinoma</keyword>
  <keyword>confocal laser endomicroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

